STAT News 08/31/2017

Indication Specific Pricing as a Pathway for Value Based Pricing

Drug Pricing Lab op-ed in STAT News discusses indication-specific pricing of Kymriah.

In an op-ed responding to the announcement of Kymriah’s launch, Anna Kaltenboeck and Dr. Peter Bach discuss the use of indication-specific pricing and outcomes-based contracting. “Two parallel features of the Novartis announcement, independent of the price of Kymriah, are harbingers of long-needed moves toward value-based pricing, an approach that directly links a drug’s price to a transparent measure of its benefit. ”

Currently, drug prices are set for treatments irrespective of patient benefit. The call for an improved pricing system based on value is gaining attention in areas such as cancer treatment and HCV treatment. Indication specific pricing (ISP) offers a potential pathway for maximizing the value of a drug across its different uses. This is particularly relevant for cancer drugs, of which 50% have more than one indication, according to an IMS analysis. Inefficiencies in pricing arise when value varies across a drug’s indications. In the article from the Journal of the American Medical Association, Dr. Peter Bach proposed to solve this issue by linking a drug’s price directly to efficacy for each of its indications. This scenario is analyzed in the table below.

A subsequent in-depth assessment by ICER highlighted practical and operational considerations for implementing ISP. A recent critique by Amitabh Chandra and Craig Garthwaite makes the case that indication-specific pricing could lead to unintended consequences, particularly in instances where a large number of patients effectively subsidizes a lower price for an indication with higher value than their own.


Key References:

Bach, Peter B. “Indication-specific pricing for cancer drugs.” JAMA 312.16 (2014): 1629-1630.

Chandra, Amitabh, and Craig Garthwaite. “The Economics of Indication-Based Drug Pricing.” New England Journal of Medicine 377.2 (2017): 103-106.

Pearson, Steven D., “Indication-Specific Pricing of Pharmaceuticals in the United States Health Care System: A Report from the 2015 ICER Membership Policy Summit.” (2016).


Research & Insights

We conduct non-partisan, independent research, and make our work accessible and informative to policymakers and the general audience alike. Browse our featured research or explore our work by article type.

Blueprints for Indication-Specific Pricing
Several approaches that rewire existing reimbursement conventions as alternatives to facilitate ISP are proposed.
Drug Pricing Lab 05/19/2020
Value-Based Pricing for Drugs: Theme and Variations
A taxonomy of the features that make a payment model truly value-based.
JAMA Viewpoint 05/02/2018
Outcomes-Based Drug Contracts Do Not Move Us Closer to Value
What steps are needed to make outcomes-based contracting a value-based approach?
Morning Consult 06/21/2017
The Conflict Between QALYs and Well-Funded Patient Advocacy Groups
The goal of a QALY is to figure out how much any given drug is worth to a society so that we, as a society, have a benchmark to evaluate the price of pharmaceutical products.
Relentless Health Value 12/10/2020
Remdesivir Less Expensive for "Government Programs"? Not So Fast.
Two options are proposed if Gilead wishes to offer the discounts to the full array of government programs.
Drug Pricing Lab 07/01/2020
Pharmaceutical Products and Their Value
Steep increases in prices and spending on prescription drugs in the United States have triggered public outrage and questions about their value.
Value in Health 03/29/2020
Understanding the Rewards of Successful Drug Development: Thinking Inside the…
The ability to charge high prices is only one component of a complex system of risks and rewards that underlies pharmaceutical innovation
NEJM 01/30/2020
Medicare Negotiation: A "Too Little" or "Too Late" Framework for…
Recent draft pieces of legislation and regulation take aim at the rising cost of drugs, targeting drugs that claim the largest share of the health care budget and that face limited competition from generics or biosimilars.
NEJM 11/28/2019
Fact Check: Time to Market for New Drugs in U.S.…
Drug prices in the U.S. are highest among developed countries, effectively setting the upper bound for reference prices elsewhere.
Drug Pricing Lab 10/11/2019
Health Affairs: Abandon Biosimilars as Biologics are Natural Monopolies
Biosimilars will not effectively lower the price of biologic drugs after the period of market exclusivity.
HA Blog 04/15/2019
Impact of President's Budget and Point of Sale Rebate Proposal…
Milliman analyzes the impact of the proposed rule to implement point of sale rebates in Medicare Part D.
Drug Pricing Lab 03/08/2019
List Price, Net Price, and the Rebate Caught in the…
Pharmacy benefit managers (PBMs), such as Express Scripts, CVS Caremark, and Optum Rx, are some of the larger companies that administer the Medicare Part D prescription drug benefit.
JAMA Viewpoint 03/06/2019

Stay up to date on our work and news